| Authors | Neef, PA Burrell, LM McDonald, CF Irving, LB Johnson, DF Steinfort, DP |
|---|---|
| Type | Accepted for Publication |
| Journal | Internal Medicine Journal |
| Year of Publication | 2017 |
| URL | http://onlinelibrary.wiley.com/wol1/doi/10.1111/imj.13518/abstract |
| DOI | http://dx.doi.org/10.1111/imj.13518 |
| Abstract | Background In patients with chronic obstructive pulmonary disease (COPD) and comorbid cardiovascular disease emerging evidence suggests a benefit in commencing cardioselective beta-blockers. Aim Our objective was to determine the safety of beta-blocker commencement during hospitalisation for acute exacerbation of COPD. Methods A retrospective cohort study of 1,071 patients hospitalised for acute exacerbation of COPD was conducted across two tertiary hospitals over a 12-month period. We identified 36 patients in whom beta-blocker therapy was commenced during admission. Primary outcome of the study was to assess cardiovascular and respiratory adverse events related to the commencement of beta-blocker therapy. Results The most common indications for beta-blockers were atrial fibrillation (53%) and acute coronary syndrome (36%). Metoprolol was the most commonly prescribed beta-blocker (75%). No patients suffered clinically significant decline of respiratory function following the commencement of a beta-blocker, including worsening respiratory symptoms, oxygen, bronchodilator or ventilation requirements. These results were demonstrable in patients with reversible airways disease and advanced COPD. Only one patient (2.8%) experienced symptomatic hypotension after 48 hours of therapy. Conclusion The commencement of cardio-selective beta-blockers during acute exacerbations of COPD appears to be well-tolerated |
http://www.ibas.org.au/what-we-do/publications/3872918
Motor neurone disease (MND) causes the body's muscles to weaken. Breathing muscle weakness means that most people affected by MND will eventually lose the ability to take a deep breath and cough strongly....
RESPIRATORY BIOMARKERS IN MOTOR NEURONE DISEASE
The inability to breathe is unfortunately the most common cause of death in people living with Motor Neurone Disease (MND). Last year, our clinical research group in Melbourne reported that breathing...
PERTH HIGHLIGHTS: TSANZSRS 2026
A huge congratulations to all our team members who participated in the excellent workshops and meetings at the TSANZSRS Annual Scientific Meeting in Perth in March 2026!
BETTER SLEEP, BETTER LIFE TIPS
For World Sleep Day, Dr. Amy Jordan joined the "Get Cereal" panelists Sam and Matilda to share top tips for better sleep, discussing the vital importance of sleep health and hygiene in a podcast interview.
Kudos to Dr. Lauren Booker & Dr. Jen Cori on their JOEM publication examining fatigue detection alarms in rural truck drivers. Their study explores the alarms' effectiveness, accuracy, and habituation, offering key insights into fatigue management.
HONORING EXCELLENCE IN RESEARCH
Congratulations to Prof. Anne Holland and A/Prof. Narelle Cox for being featured in the NHMRC's 10 of the Best - 16th Edition. Their work exemplifies groundbreaking research delivering extraordinary outcomes.
© 2026 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
